Objective: assess the effectiveness of a new method for classifying EEG recording features through the use of tags within reports. We present feature prevalence in a sample of patients with toxic-metabolic encephalopathy and discuss the advantages of this approach over existing classification systems.

Methods: during EEG report creation, tags reflecting background activity, epileptiform features and periodic discharges were selected according to the findings of each recording. Reports including the tags have been collected and processed by the EEG report parser script written in PHP language. The resulting spreadsheet was analysed to calculate the prevalence and type of EEG features in a sample group of patients with toxic-metabolic encephalopathy.

Results: tag checking and extraction were very little time-consuming processes. Considering 5784 EEG recordings performed either in inpatients or outpatients over 2 years, toxic-metabolic aetiology was tagged in 218 (3.8 %). The most frequent background feature was severe slowing (5-6 Hz frequency), occurring in 79 (36.2 %). Epileptiform abnormalities were rare, reaching a maximum of 10 (4.6 %). Triphasic waves were tagged in 43 (19.7 %) recordings.

Conclusions: tagging and parsing processes are very fast and integrated into the daily routine. Sample analysis in patients with toxic-metabolic encephalopathies showed EEG slowing as the prevalent feature, while triphasic waves occurred in a minority of recordings. Existing software such as "SCORE" (Holberg EEG) requires the replacement of the currently used software for EEG reporting, minimizing additional costs and training. EEG Report Parser is free and open-source software, so it can be freely adopted, modified and redistributed, allowing further improvement and adaptability.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmpb.2023.107836DOI Listing

Publication Analysis

Top Keywords

patients toxic-metabolic
12
eeg report
12
eeg
9
eeg features
8
report parser
8
triphasic waves
8
tagging eeg
4
features
4
features exam
4
exam reports
4

Similar Publications

Background And Objectives: The term rapid progressive dementia (RPD) may be applied to patients who develop dementia within 1 year or complete incapacitation within 2 years of the first symptom of impairment. However, in select cases, cognitive impairment may emerge abruptly, with symptoms evolving across hours or days. We sought to determine the frequency, etiologies, and factors that associated with ultra-RPD.

View Article and Find Full Text PDF

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

Nat Rev Drug Discov

November 2024

Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic dysfunction-associated steatohepatitis (MASH) have become a global epidemic and are driven by chronic overnutrition and multiple genetic susceptibility factors. The physiological outcomes include hepatocyte death, liver inflammation and cirrhosis. The first therapeutic for MASLD and MASH, resmetirom, has recently been approved for clinical use and has energized this therapeutic space.

View Article and Find Full Text PDF

The metabolic crosstalk of cancer-associated fibroblasts and tumor cells: Recent advances and future perspectives.

Biochim Biophys Acta Rev Cancer

November 2024

Hangzhou Cancer Institution, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou Cancer Hospital, 310002, China. Electronic address:

Tumor cells grow in a microenvironment with a lack of nutrients and oxygen. Cancer-associated fibroblasts (CAFs) as one major component of tumor microenvironment have strong ability to survive under stressful conditions through metabolic remodelling. Furthermore, CAFs are educated by tumor cells and help them adapt to the hostile microenvironment through their metabolic communication.

View Article and Find Full Text PDF

Epilepsy with eyelid myoclonia in a patient with ATP1A3-related neurologic disorder.

Epileptic Disord

December 2024

Department of Pediatric Epileptology, Functional Neurology and Sleep Disorders, Hôpital Femme Mère Enfant, University Hospitals of Lyon (HCL), Member of ERN EpiCARE, Lyon, France.

Article Synopsis
  • An 11-year-old Polish girl experienced episodes of decreased consciousness, paralysis, movement disorders, slurred speech, swallowing difficulties, and abnormal eye movements, but extensive testing did not identify a clear cause.
  • Genetic testing revealed a new mutation in the ATP1A3 gene, which has been associated with various neurological disorders, including epilepsy.
  • Video-EEG monitoring confirmed non-epileptic causes of her hemidystonia episodes, but also showed signs of a specific type of epilepsy related to her ATP1A3 mutation, highlighting the overlap of symptoms from different ATP1A3-related syndromes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!